REMS Patent Safe For Now, But Pharma Still Facing PTO ‘Death Squads’
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent Trial and Appeal Board finds Jazz’s REMS patent does not address sales transactions; Par and Amneal are now seeking inter partes review.